Rifampin versus isoniazid for the treatment of latent tuberculosis

Not Applicable

Completed

• Conditions: atent tuberculosis (TB) Infection; Infections and Infestations; Tuberculosis

• Registration Number: ISRCTN41241584
• Lead Sponsor: The Research Institute of the McGill University Health Centre (Canada)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09-26
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1260

Inclusion Criteria

1. Close or casual contact of an active case pulmonary Tuberculosis (TB)
2. Aged 18 years and older, either sex
3. Documented tuberculin conversion within five years
4. Human immunodeficiency virus (HIV) positive, or other immune suppressed condition (e.g. corticosteroid therapy)
5. Apical/upper lobe fibronodular disease (with area greater than 2 cm^2), or other radiographic abnormalities
6. Underweight, diabetes, renal failure, or other medical risk factors
7. Recent (less than two years) arrival from country/region with TB incidence greater than 100/100,000

Exclusion Criteria

1. Low risk reactors
2. Patients who were contacts of known INH resistant case
3. Known HIV-infected individuals on triple anti-retroviral therapy
4. Women of child bearing age taking oral contraceptives
5. Patients on any other medication with clinically important drug interaction with INH or RIF

Study & Design

• Study Type: Interventional
• Study Design: Not specified